

Researchers develop novel immunotherapy to target colorectal cancer

13 February 2018, by Ziba Kashef




Image depicts intestinal tumor cell death (red stain) after anti-DKK2 antibody treatment. Cell nuclei are stained blue. Credit: Yale University

A Yale-led research team has developed an antibody that blocks tumors in animal models of colorectal cancer. If the finding is confirmed in clinical trials, the antibody-based treatment could become an effective weapon against colorectal cancer, and possibly other cancers, that resist current immunotherapies, the researchers said.

The study was published in *Nature Medicine*.

Certain cancers fail to respond to existing immunotherapy drugs that are designed to unleash the body's immune system against tumors. To investigate alternative approaches to these cancers, the Yale-led team focused on a protein molecule, DKK2, an inhibitor of Wnt proteins. Wnt proteins had been previously implicated in the promotion of tumors.

To explore the molecule's role in [cancer](#), the researchers crossbred a mouse model of [colorectal cancer](#) with mice lacking DKK2. They discovered that the offspring had fewer and smaller tumors, according to senior study author and

professor of pharmacology Dan Wu.

"We found that this Wnt inhibitor, DKK2, which was thought to inhibit tumor formation, promoted tumors through suppression of [tumor](#) immunity," Wu said. Additionally, they learned "if you inactivate, or neutralize, or blockade this inhibitor, it causes reduction of [tumor formation](#) through activation of the host's immune system."

Based on this finding, the researchers developed an antibody to "inhibit the inhibitor" and target colorectal cancers. They also observed that the antibody was effective in blocking a subset of melanomas when used with other immunotherapy drugs.

Wu, who is a member of Yale Cancer Center, believes that the antibody has potential as a new immunotherapy inhibitor to treat these and other cancers.

More information: Qian Xiao et al. DKK2 imparts tumor immunity evasion through β -catenin-independent suppression of cytotoxic immune-cell activation, *Nature Medicine* (2018). [DOI: 10.1038/nm.4496](#)

Provided by Yale University

APA citation: Researchers develop novel immunotherapy to target colorectal cancer (2018, February 13) retrieved 17 October 2021 from <https://medicalxpress.com/news/2018-02-immunotherapy-colorectal-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.